Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trialss

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 3, 2013, Pages 635-644

  Van De Steeg, E ^a   Kleemann, R ^a   Jansen, H T ^a   VanDuyvenvoorde, W ^a   Offerman, E H ^a   Wortelboer, H M ^a   DeGroot, J ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ATORVASTATIN H 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; L 472225; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; PRAVASTATIN H 3; ROSUVASTATIN; ROSUVASTATIN H 3; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; DRUG UPTAKE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER; META ANALYSIS (TOPIC); MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SPECIES DIFFERENCE; SYSTEMATIC REVIEW (TOPIC); TRANSGENIC MOUSE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; BODY WEIGHT; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EATING; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; MICE; MICE, TRANSGENIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887950105     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208595     Document Type: Article

References (35)

1. Arrowsmith J (2012) A decade of change. Nat Rev Drug Discov 11:17-18.
2. Arrowsmith J (2011) Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 10:328-329.
3. Beth Smith M.E., Lee JL, Haney E, Carson S. (2009) HMG-CoA reductase inhibitors (statins) and fixed-dose combination products contatining a statin - update 5 (Oregon Health Resources Commission).
4. Booth B and Zemmel R (2004) Prospects for productivity. Nat Rev Drug Discov 3: 451-456. (Pubitemid 38618127)
5. DeGorter MK, Urquhart BL, Gradhand U, Tirona R.G., and Kim RB (2012) Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intra-individual variability in human subjects. J Clin Pharmacol 52:1689-1697.
6. *3-Leiden transgenic mice. J Cardiovasc Pharmacol 42:63-70. (Pubitemid 36791351)
7. *3-leiden mice. J Cardiovasc Pharmacol 45:53-60. (Pubitemid 40039756)
8. Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy K.E., van de Steeg E, Wagenaar E, Beijnen JH, and Schinkel AH (2012) Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm 9: 2497-2504.
9. Kleemann R and Kooistra T (2005) HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr Drug Targets Cardiovasc Haematol Disord 5:441-453. (Pubitemid 43012568)
10. *3-Leiden transgenic mice: evidence for antiinflammatory effects of rosu-vastatin. Circulation 108:1368-1374. (Pubitemid 37174416)
11. Kola I and Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715. (Pubitemid 39173511)
12. Lau YY, Okochi H, Huang Y., and Benet LZ (2006) Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175-1181.
13. Liao JK and Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89-118. (Pubitemid 40261799)
14. Liengme BV (2010) Exceltips: regression analysis confidence interval (http://people.stfx.ca/bliengme/ExcelTips/RegressionAnalysisConfidence2.htm).
15. McTaggart F, Buckett L, Davidson R., Holdgate G, McCormick A, Schneck D., Smith G, and Warwick M (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87 (5A):28B-32B. (Pubitemid 32274242)
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143-3421.
17. Neuvonen PJ, Backman JT, and Niemi M (2008) Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pra-vastatin. Clin Pharmacokinet 47:463-474. (Pubitemid 351861958)
18. Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80: 565-581. (Pubitemid 44908269)
19. Nezasa K, Higaki K, Matsumura T., Inazawa K, Hasegawa H, Nakano M., and Koike M (2002) Liver-specific distribution of rosuvastatin in rats: comparison with pra-vastatin and simvastatin. Drug Metab Dispos 30:1158-1163. (Pubitemid 35265820)
20. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting poly-peptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
21. Paul SM, Mytelka DS, Dunwiddie C.T., Persinger CC, Munos BH, Lindborg SR, and Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214.
22. Peng SX, Rockafellow BA, Skedzielewski T.M., Huebert ND, and Hageman W (2009) Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. J Pharm Sci 98:1877-1884.
23. Tiwari R and Pathak K (2011) Nanostructured lipid carrier versus solid lipid nano-particles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232-243.
24. O3-Leiden transgenic mice. J Mol Cell Cardiol 35:109-118. (Pubitemid 36286973)
25. *3Leiden transgenic mice. J Hypertens 25: 2454-2462. (Pubitemid 350060384)
26. *3-Leiden transgenic mice as a test model for hypolipidaemic drugs. Arzneimittelforschung 48:396-402. (Pubitemid 28197852)
27. van Vlijmen B.J., van den Maagdenberg AM, Gijbels MJ, van der Boom H, Hogen-Esch H, Frants RR, Hofker MH, and Havekes LM (1994) Diet-induced hyper-lipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93:1403-1410. (Pubitemid 24116375)
28. van de Poll SW, Römer TJ, Volger O.L., Delsing DJ, Bakker Schut TC, Princen HM, Havekes LM, Jukema JW, van Der Laarse A, and Puppels GJ (2001) Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice. Arterioscler Thromb Vasc Biol 21: 1630-1635. (Pubitemid 34215583)
29. *3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 25: 161-167. (Pubitemid 40054270)
30. Verschuren L, Radonjic M, Wielinga P.Y., Kelder T., Kooistra T, van Ommen B, and Kleemann R (2012) Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenet Genomics 22:837-845.
31. Wang YX, Martin-McNulty B, Huw L.Y., da Cunha V, Post J, Hinchman J., Vergona R, Sullivan ME, Dole W, and Kauser K (2002) Anti-atherosclerotic effect of simvas-tatin depends on the presence of apolipoprotein E. Atherosclerosis 162:23-31. (Pubitemid 34327338)
32. Weng TC, Yang YH, Lin S.J., and Tai SH (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35:139-151.
33. Zadelaar S, Kleemann R, Verschuren L., de Vries-Van der Weij J, van der Hoorn JW, Princen HM, and Kooistra T (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27:1706-1721. (Pubitemid 47207165)
34. Zhang Y and Yang Z (2007) HPLC determiniation of lovastatin in rat tissue. Chro-matographia 66:487-491. (Pubitemid 47497696)
35. Zhu Y, D'Agostino J, and Zhang QY (2011) Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab Dispos 39:939-943.